EP1429782A4 - Modulation of vitamin storage - Google Patents

Modulation of vitamin storage

Info

Publication number
EP1429782A4
EP1429782A4 EP02799356A EP02799356A EP1429782A4 EP 1429782 A4 EP1429782 A4 EP 1429782A4 EP 02799356 A EP02799356 A EP 02799356A EP 02799356 A EP02799356 A EP 02799356A EP 1429782 A4 EP1429782 A4 EP 1429782A4
Authority
EP
European Patent Office
Prior art keywords
modulation
vitamin storage
vitamin
storage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02799356A
Other languages
German (de)
French (fr)
Other versions
EP1429782A1 (en
Inventor
Simon Michael West
David Kannar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vital Health Sciences Pty Ltd
Original Assignee
Vital Health Sciences Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU2001/001206 external-priority patent/WO2002026238A1/en
Priority claimed from AU2002951045A external-priority patent/AU2002951045A0/en
Application filed by Vital Health Sciences Pty Ltd filed Critical Vital Health Sciences Pty Ltd
Publication of EP1429782A1 publication Critical patent/EP1429782A1/en
Publication of EP1429782A4 publication Critical patent/EP1429782A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02799356A 2001-09-26 2002-09-26 Modulation of vitamin storage Ceased EP1429782A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
WOPCT/AU01/01206 2001-09-26
PCT/AU2001/001206 WO2002026238A1 (en) 2000-09-26 2001-09-26 Phosphate derivative supplements
AU2002951045A AU2002951045A0 (en) 2002-08-27 2002-08-27 Method of supplementing nascent endogenous storage forms
AU2002951045 2002-08-27
PCT/AU2002/001321 WO2003026673A1 (en) 2001-09-26 2002-09-26 Modulation of vitamin storage

Publications (2)

Publication Number Publication Date
EP1429782A1 EP1429782A1 (en) 2004-06-23
EP1429782A4 true EP1429782A4 (en) 2005-02-02

Family

ID=25613914

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02799356A Ceased EP1429782A4 (en) 2001-09-26 2002-09-26 Modulation of vitamin storage

Country Status (5)

Country Link
EP (1) EP1429782A4 (en)
JP (1) JP2005515969A (en)
CA (1) CA2458279A1 (en)
MX (1) MXPA04001779A (en)
WO (1) WO2003026673A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
KR20050086954A (en) * 2003-01-17 2005-08-30 바이탈 헬스 사이언시즈 피티와이 리미티드 Compounds having anti-proliferative properties
BRPI0508125A (en) * 2004-03-03 2007-07-17 Vital Health Sciences Pty Ltd alkaloid formulation, method for improving the effectiveness of an alkaloid, use of the reaction product of one or more alkaloids with one or more phosphate derivatives of one or more electron transfer agents, together with excipients and pharmaceutical composition
BRPI0513673B8 (en) * 2004-08-03 2021-07-27 Vital Health Sciences Pty Ltd method for producing a drug to increase the efficacy and transport of enterally administered biologically active compounds, and pharmaceutical composition
EP1861091B1 (en) * 2005-03-03 2013-12-11 Vital Health Sciences Pty Ltd. Compounds having lipid lowering properties
JP2008531602A (en) * 2005-03-03 2008-08-14 バイタル ヘルス サイエンシズ プロプライアタリー リミティド Compounds with anticancer properties
CA2611831C (en) 2005-06-17 2014-09-16 Vital Health Sciences Pty Ltd. A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
EP2531047A4 (en) 2010-02-05 2014-03-19 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
KR20120115991A (en) * 2010-02-05 2012-10-19 포스파제닉스 리미티드 Carrier composition
MX2012011355A (en) 2010-03-30 2012-11-30 Phosphagenics Ltd Transdermal delivery patch.
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
CA3007587C (en) 2015-12-09 2023-12-05 Phosphagenics Limited Pharmaceutical formulation
JP7198754B2 (en) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド Method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430045A2 (en) * 1989-11-21 1991-06-05 Senju Pharmaceutical Co., Ltd. Ascorbic acid tocopheryl phosphate diesters for inhibition of Maillard's reaction
US5607921A (en) * 1994-01-31 1997-03-04 L'oreal Stabilized cosmetic or dermatological composition containing several precursors of the same active agent in order to maximize its release, and use thereof
US5776915A (en) * 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
JPH1143436A (en) * 1997-07-25 1999-02-16 Showa Denko Kk Medicine for preventing/treating periphery blood stream disorder
JPH11199424A (en) * 1997-12-26 1999-07-27 Nonogawa Shoji Kk Skin preparation for external use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
US5643597A (en) * 1991-08-01 1997-07-01 Lvmh Recherche Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained
FR2679904A1 (en) * 1991-08-01 1993-02-05 Lvmh Rech Use of a tocopherol phosphate, or of one of its derivatives, in the preparation of cosmetic or pharmaceutical compositions and compositions thus obtained
WO1993015731A1 (en) * 1992-02-14 1993-08-19 Robert Lamb Phosphate derivatives of vitamin e to protect cells from effects of aging and injury
JPH05286848A (en) * 1992-04-10 1993-11-02 Senju Pharmaceut Co Ltd Bathing agent
JP3362501B2 (en) * 1994-04-28 2003-01-07 千寿製薬株式会社 Corneal disorder treatment
JPH10155429A (en) * 1996-11-27 1998-06-16 Showa Denko Kk Method for supplying vitamin e to animals and tocopherol phosphate for animals or its salts composition
WO2002026238A1 (en) * 2000-09-26 2002-04-04 Vital Health Sciences Pty Ltd. Phosphate derivative supplements

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430045A2 (en) * 1989-11-21 1991-06-05 Senju Pharmaceutical Co., Ltd. Ascorbic acid tocopheryl phosphate diesters for inhibition of Maillard's reaction
US5607921A (en) * 1994-01-31 1997-03-04 L'oreal Stabilized cosmetic or dermatological composition containing several precursors of the same active agent in order to maximize its release, and use thereof
JPH1143436A (en) * 1997-07-25 1999-02-16 Showa Denko Kk Medicine for preventing/treating periphery blood stream disorder
US5776915A (en) * 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
JPH11199424A (en) * 1997-12-26 1999-07-27 Nonogawa Shoji Kk Skin preparation for external use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 05 31 May 1999 (1999-05-31) *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 12 29 October 1999 (1999-10-29) *
See also references of WO03026673A1 *

Also Published As

Publication number Publication date
EP1429782A1 (en) 2004-06-23
MXPA04001779A (en) 2004-05-31
WO2003026673A1 (en) 2003-04-03
JP2005515969A (en) 2005-06-02
CA2458279A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
AU2002255329A1 (en) Stable solution of reduced coenzyme Q
HK1067907A1 (en) Amplifier modulation
TW487177U (en) Anti-dust lid of connecting slot
HUP0401534A3 (en) Modified factor ix
AU2002244203A1 (en) Devices and methods for prolonging the storage life of produce
TW509023U (en) Cosmetic case
EP1429782A4 (en) Modulation of vitamin storage
AU2003252072A8 (en) Modulation of protein kinase c-iota expression
AU2002366788A1 (en) Antisense modulation of ship-1 expression
AU2002318139A1 (en) Antisense modulation of src-c expression
GB0126781D0 (en) Modulation
GB0124321D0 (en) Modulation determination
AU2002357102A1 (en) Antisense modulation of cd36l1 expression
AU2003257966A1 (en) Antisense modulation of lar expression
IL162747A0 (en) Modulation of heat-shock-protein-based immunotherapies
AU2003295790A8 (en) Modulation of iap-like expression
AU2002322551A1 (en) Antisense modulation of rip2 expression
AU2002347809A1 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression
AU2003290763A8 (en) Modulation of jumonji expression
GB0106857D0 (en) Storage
AU2002329838A1 (en) Modulation of appl expression
AU2002244086A1 (en) Antisense modulation of recql4 expression
WO2003048376A9 (en) Modulation of immune-cell related disorders using il-1hy2
AU2002353153A8 (en) Antisense modulation of tfap2c expression
AU2002362942A1 (en) Modulation of tor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040323

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041221

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20070708